significantNew research
French nationwide study: largest cohort of 57 HUV patients
Hypocomplementemic Urticarial Vasculitis Syndrome →Summary
Jachiet et al. (2015) reported the largest cohort study of HUV with 57 patients, establishing frequency data for systemic manifestations: musculoskeletal 82%, ocular 56%, angioedema 51%, pulmonary 19%, renal 14%. Evaluated treatment efficacy including hydroxychloroquine, colchicine, and corticosteroids.
Related treatments
Source
Grade Bretrospective study
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients
Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F, et al. · Arthritis Rheumatol · 2015
- •Largest cohort study: 57 patients with HUV
- •Angioedema in 51%, musculoskeletal 82%, ocular 56%, pulmonary 19%, renal 14%
- •Evaluated treatment efficacy via time-to-treatment failure
More from Hypocomplementemic Urticarial Vasculitis Syndrome
incrementalTreatment update
JAK inhibition shows partial response in DNASE1L3-deficient HUVS
incrementalTreatment update
Pediatric HUVS: rituximab most effective in long-term follow-up
incrementalNew research
Novel DNASE1L3 variant in Emirati families demonstrates secretion defect mechanism
incrementalepidemiology
Systematic review estimates HUVS prevalence at fewer than 1 per million
ID: hypocomplementemic-urticarial-vasculitis-syndrome-update-2Type: new_researchImpact: significant